Thomas McElrath

Thomas McElrath has had a long and distinguished career in the medical field. Thomas began their work in 2000 as an Attending in Maternal-Fetal Medicine at Mass General Brigham. In 2014, they joined NX PRENATAL INC. as a Principal Investigator and Scientific Advisory Board member. In 2017, they became a Principal Investigator at Mirvie. In 2019, they joined Harvard Medical School as a Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard T.H. Chan School of Public Health as an Associate Professor of Epidemiology, Roche as a member of the Ocrelizumab Pregnancy and Lactation Advisory Committee, Comanche Biopharma as a Research and Product Development Consultant, and Tectonic Therapeutic, Inc. as a Research and Product Development Consultant.

Thomas McElrath obtained a Bachelor's degree in Anthropology from the University of Michigan between 1982 and 1987. Thomas then attended the University of Pennsylvania from 1990 to 1993, where they earned a Doctor of Philosophy in Demography and Population Studies. Following that, they attended Harvard Medical School from 1992 to 1996 and obtained a Doctor of Medicine. In 1984 and 1985, they also attended the University of Freiburg for German Language and Literature. In 2003, they were Board Certified in Obstetrics and Gynecology by the American Board of Obstetrics and Gynecology (ABOG). In 2007, they were additionally Board Certified in Maternal-Fetal Medicine by the same institution. Finally, in 2023, they obtained the CITI Good Clinical Practice Course from the CITI Program.